Metachronous Hepatic Angiosarcoma Presenting as a Mimic of Recurrent Hepatocellular Carcinoma

  • Eric K. C. Lau
  • Bernette Tsai
  • Harry Morrison
  • Michael Deftos
  • Albert Y. Lin
Case Report


Primary hepatic angiosarcoma (PHA) is the third most common primary liver malignancy, after hepatocellular carcinoma and cholangiocarcinoma, accounting for 2% of primary liver malignancies and less than 1% of all sarcomas [1, 2]. PHA has been known to present in men over 60 years of age and has been associated with neurofibromatosis-1, anabolic steroids, hemochromatosis, vinyl chloride, thorotrast radiocontrast, and arsenic, although most cases are idiopathic [2, 3]. PHA is a very aggressive malignancy with a historical median survival of only 5 months despite treatment [4]. Our case highlights how this deadly disease can present as a mimic of recurrent hepatocellular carcinoma (HCC) in a patient with known prior HCC.

Case Report

The patient was a 62-year-old Hispanic male with a past medical history of hepatitis C-related liver cirrhosis treated with an interferon-based regimen. He was diagnosed with HCC via triphasic liver computed tomography (CT) showing a 2-cm...


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23(1):47–63.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Huang NC, Kuo YC, Chiang JC, Hung SY, Wang HM, Hung YM, et al. Hepatic angiosarcoma may have fair survival nowadays. Medicine (Baltimore). 2015;94(19):e816.CrossRefGoogle Scholar
  3. 3.
    Kim HR, Rha SY, Cheon SH, Roh JK, Park YN, Yoo NC. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. Ann Oncol. 2009;20(4):780–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Zheng YW, Zhang XW, Zhang JL, Hui ZZ, du WJ, Li RM, et al. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol. 2014;29(5):906–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Koyama T, Fletcher JG, Johnson CD, Kuo MS, Notohara K, Burgart LJ. Primary hepatic angiosarcoma: findings at CT and MRI. Radiology. 2002;222(3):667–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273(1):30–50.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Park YS, Kim JH, Kim KW, Lee IS, Yoon HK, Ko GY, et al. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. Clin Radiol. 2009;64(8):779–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Rao P, Lahat G, Arnold C, Gavino AC, Lahat S, Hornick JL, et al. Angiosarcoma: a tissue microarray study with diagnostic implications. Am J Dermatopathol. 2013;35(4):432–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25(8):1061–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Ordóñez NG. Immunohistochemical endothelial markers: a review. Adv Anat Pathol. 2012;19(5):281–95.CrossRefPubMedGoogle Scholar
  11. 11.
    Bioulac-Sage P, Laumonier H, Laurent C, Blanc J, Balabaud C. Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis. 2008;28(3):302–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Weitz J, Klimstra DS, Cymes K, Jarnagin WR, D'Angelica M, la Quaglia MP, et al. Management of primary liver sarcomas. Cancer. 2007;109(7):1391–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Almogy G, Lieberman S, Gips M, Pappo O, Edden Y, Jurim O, et al. Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol. 2004;30(4):421–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Ray-Coquard I, Italiano A, Bompas E, le Cesne A, Robin YM, Chevreau C, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17(2):260–6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kojiro M, Kawano Y, Kawasaki H, Nakashima T, Ikezaki H. Thorotrast-induced hepatic angiosarcoma, and combined hepatocellular and cholangiocarcinoma in a single patient. Cancer. 1982;49(10):2161–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Athanasopoulos PG, Hadjittofi C, Luong TV, O’Beirne J, Sharma D. Synchronous hepatic epithelioid hemangioendothelioma and hepatocellular carcinoma: first case report in the literature and challenges. Medicine (Baltimore). 2015;94(34):e1377.CrossRefGoogle Scholar
  18. 18.
    Shah BK, Kandel P, Khanal A, et al. Second primary malignancies in hepatocellular cancer—a US population-based study. Anticancer Res. 2016;36(7):3511–4.PubMedGoogle Scholar
  19. 19.
    Nzeako UC, Goodman ZD, Ishak KG. Association of hepatocellular carcinoma in north American patients with extrahepatic primary malignancies. Cancer. 1994;74(10):2765–71.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineSanta Clara Valley Medical CenterSan JoseUSA
  2. 2.Division of Primary CareSanta Clara Valley Medical CenterSan JoseUSA
  3. 3.Department of RadiologySanta Clara Valley Medical CenterSan JoseUSA
  4. 4.Department of PathologySanta Clara Valley Medical CenterSan JoseUSA
  5. 5.Palo AltoVA Palo Alto Health Care SystemPalo AltoUSA
  6. 6.School of MedicineStanford UniversityStanfordUSA

Personalised recommendations